The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women-Reference-Cited by-同舟云学术

The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women

Published:2003-05 Issue:7 Volume:39 Page:861-869
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Robertson J.F.R.,Blamey R.W.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference53 articles.

1. On the treatment of inoperable cases of carcinoma of the mamma;Beatson;Lancet,1896

2. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, ‘Zoladex’;Furr;Horm. Res.,1989

3. Oophorectomy for advanced carcinoma of the breast;Veronesi;Surg. Gynecol. Obstet.,1975

4. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer;Ingle;J. Clin. Oncol.,1986

5. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer;Oriana;Eur. J. Surg. Oncol.,1989

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes;Cancer Treatment Reviews;2024-09

2. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results;Annals of Oncology;2024-08

3. Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer;npj Breast Cancer;2024-01-19

4. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance;Cancer Research;2023-09-19

5. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis;Cancers;2023-03-06